FY2026 EPS Estimate for Wave Life Sciences Cut by Analyst

Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Equities research analysts at B. Riley dropped their FY2026 earnings per share (EPS) estimates for shares of Wave Life Sciences in a research report issued on Thursday, April 10th. B. Riley analyst M. El-Saadi now expects that the company will earn ($1.15) per share for the year, down from their prior estimate of ($0.96). The consensus estimate for Wave Life Sciences' current full-year earnings is ($1.14) per share. B. Riley also issued estimates for Wave Life Sciences' FY2027 earnings at ($0.25) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.84 EPS.

WVE has been the subject of a number of other research reports. HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of Wave Life Sciences in a report on Wednesday, March 26th. Jefferies Financial Group assumed coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They set a "buy" rating and a $26.00 price objective on the stock. StockNews.com upgraded shares of Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Finally, Wedbush began coverage on shares of Wave Life Sciences in a report on Tuesday, April 8th. They issued an "outperform" rating and a $18.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $22.18.

Wave Life Sciences Stock Up 1.4 %

Shares of NASDAQ WVE traded up $0.08 during midday trading on Monday, reaching $5.92. 947,955 shares of the company's stock traded hands, compared to its average volume of 1,191,065. The company has a market cap of $908.64 million, a price-to-earnings ratio of -5.33 and a beta of -0.93. The stock's 50 day simple moving average is $8.92 and its 200-day simple moving average is $11.56. Wave Life Sciences has a one year low of $4.25 and a one year high of $16.74.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last issued its earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.34. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The company had revenue of $83.75 million for the quarter, compared to analysts' expectations of $25.60 million.

Insider Buying and Selling at Wave Life Sciences

In related news, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the completion of the sale, the director now owns 16,115 shares of the company's stock, valued at $157,443.55. The trade was a 39.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Paul Bolno sold 169,025 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the completion of the transaction, the chief executive officer now owns 338,351 shares in the company, valued at approximately $3,238,019.07. This trade represents a 33.31 % decrease in their position. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by company insiders.

Institutional Trading of Wave Life Sciences

Several large investors have recently made changes to their positions in WVE. GF Fund Management CO. LTD. purchased a new position in shares of Wave Life Sciences during the fourth quarter worth $40,000. Quarry LP acquired a new stake in Wave Life Sciences during the 4th quarter worth about $62,000. KBC Group NV purchased a new position in shares of Wave Life Sciences during the 4th quarter valued at about $67,000. Summit Investment Advisors Inc. raised its stake in shares of Wave Life Sciences by 31.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company's stock valued at $119,000 after buying an additional 2,308 shares during the last quarter. Finally, Orion Portfolio Solutions LLC acquired a new position in shares of Wave Life Sciences in the 3rd quarter valued at about $123,000. 89.73% of the stock is owned by hedge funds and other institutional investors.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.